A Study On The Association Of The Serum Concentration And The Promoter 5A/6A Polymorphism Of Matrix Metalloproteinase-3 And The Serum Concentration Of Interleukin-1 With Coronary Heart Disease

A study on the association of the serum concentration andthe promoter 5A/6A polymorphism of MatrixMetalloproteinase-3 and the serum concentration ofInterleukin-1 with Coronary Heart DiseaseAbstract Objective: To investigate the association of the serum concentration and thepromoter 5A/6A polymorphism of Matrix Metalloproteinase-3 and the serum concentration of Interleukin-1 with Coronary Heart Disease Method: The study was composed of 137 CHD patients and 106 control subjects without CHD. The diagnoses of both groups were confirmed by coronary angiography. The 137 CHD patients were divided into AMI group, UAP group and SA group according to World Health Organization criteria. The serum concentration of Matrix Metalloproteinase-3 was measured by ELISA. The serum concentration of Interleukin-1 was measured by radioimmunoassay. MMP-3 promoter gene containing the 5A/6A polymorphism was amplified by polymerase chain reaction(PCR). The PCR products were digested by Tthlll I and then were separated by electrophoresis on agarose gel.Result: The distribution of MMP-3 genotype were not significantly different between CHD patients and controls. So was it between AMI patients and controls. Serum MMP-3 level was significantly higher in CHD group than in controls(49. 005 + 34. 576 vs 39. 149 + 24. 155 , P<0. 05). So was it in AMI group than in controls, UAP group and SA group (56. 815 + 38.932, 39.149 + 24.155,41.64 + 29.180,33.336 + 20.755; P<0.01, P<0. 05, P<0. 01) . Serum MMP-3 levels were not significantly differentamong genotypes and among controls, UAP group and SA group. Serum MMP-3 levels were not significantly different no matter how much coronary arteries were involved in CHD group. Serum IL-1 level was significantly higher in CHD group than in controls (0.229 + 0. 145 vs 0. 175 + 0. 120, P<0. 01) . So was it in AMI group than in controls, UAP group and SA group (0. 266 + 0.134, 0. 175 + 0. 120, 0.185 + 0. 129, 0.151 + 0.125; P<0. 01, P<0. 01, P<0. 05) . Serum IL-llevels were not significantly different among controls, UAP group and SA group. No significantly difference of serum IL-llevels were found among different numbers of coronary arteries that were involved in CHD. There is a strong positive correlation between both serum level of MMP-3 and IL-1 in AMI group(r=0. 314, P<0. 05) .Conclusion: We found no association between the 5A/6A polymorphism in the MMP-3 gene and risk of CHD and AMI. The higher serum levels of MMP-3 and IL-1 are strong association with AMI, but no association with the number of coronary arteries that were involved in CHD. It may suggest that MMP-3 and IL-1 have a strong relation with rupture of atherosclerosis plaque and they are the important disease markers of AMI. They may play important roles in the induction of rupture of atherosclerosis plaque. There is a strong positive correlation between both serum levels of MMP-3 and IL-1 in AMI. It may implicate that they are regulated by each other during AMI.